INTRODUCTION: Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting. METHODS: Data were extracted from de-identified electronic medical records from an obesity management clinic in Switzerland. Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71). RESULTS: Median persistence on liraglutide was 6.8 months. Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg. Mean 7-month weight change from baseline in the full cohort was -4.1 kg (95% confidence interval: -5.0, -3.2; p < 0.001; -4.2%). Weight change was -4.4 kg (-4.7%) in the ≥4-month persistence subgroup at 4 months, -5.1 kg (-5.3%) in the ≥7-month persistence subgroup at 7 months, and -7.5 kg (-7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001). In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively. Weight loss did not differ significantly according to history of bariatric surgery (p = 0.94). Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; p = 0.018), with no significant changes in systolic blood pressure. Approximately two-thirds of patients did not have health insurance that could cover the cost of liraglutide. CONCLUSION: In a real-world setting with low insurance coverage and with most patients not reaching the recommended maintenance dose of 3.0 mg, the use of liraglutide, in combination with diet and exercise, was associated with clinically meaningful weight loss.
INTRODUCTION: Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting. METHODS: Data were extracted from de-identified electronic medical records from an obesity management clinic in Switzerland. Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71). RESULTS: Median persistence on liraglutide was 6.8 months. Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg. Mean 7-month weight change from baseline in the full cohort was -4.1 kg (95% confidence interval: -5.0, -3.2; p < 0.001; -4.2%). Weight change was -4.4 kg (-4.7%) in the ≥4-month persistence subgroup at 4 months, -5.1 kg (-5.3%) in the ≥7-month persistence subgroup at 7 months, and -7.5 kg (-7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001). In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively. Weight loss did not differ significantly according to history of bariatric surgery (p = 0.94). Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; p = 0.018), with no significant changes in systolic blood pressure. Approximately two-thirds of patients did not have health insurance that could cover the cost of liraglutide. CONCLUSION: In a real-world setting with low insurance coverage and with most patients not reaching the recommended maintenance dose of 3.0 mg, the use of liraglutide, in combination with diet and exercise, was associated with clinically meaningful weight loss.
Authors: F Ferrari; P Fierabracci; G Salvetti; R Jaccheri; J Vitti; G Scartabelli; A Meola; S Magno; G Ceccarini; F Santini Journal: J Endocrinol Invest Date: 2020-06-27 Impact factor: 4.256
Authors: John E Blundell; Jennifer Lyn Baker; Emma Boyland; Ellen Blaak; Jadwiga Charzewska; Stefaan de Henauw; Gema Frühbeck; Marcela Gonzalez-Gross; Johannes Hebebrand; Lotte Holm; Vilma Kriaucioniene; Lauren Lissner; Jean-Michel Oppert; Karin Schindler; Ana Lúcia Silva; Euan Woodward Journal: Obes Facts Date: 2017-02-11 Impact factor: 3.942
Authors: Mohamed Suliman; Adam Buckley; Alia Al Tikriti; Tricia Tan; Carel W le Roux; Nader Lessan; Maha Barakat Journal: Diabetes Obes Metab Date: 2019-03-25 Impact factor: 6.577
Authors: Zubaidah Nor Hanipah; Elie C Nasr; Emre Bucak; Philip R Schauer; Ali Aminian; Stacy A Brethauer; Derrick Cetin Journal: Surg Obes Relat Dis Date: 2017-10-09 Impact factor: 4.734
Authors: Carel W le Roux; Arne Astrup; Ken Fujioka; Frank Greenway; David C W Lau; Luc Van Gaal; Rafael Violante Ortiz; John P H Wilding; Trine V Skjøth; Linda Shapiro Manning; Xavier Pi-Sunyer Journal: Lancet Date: 2017-02-23 Impact factor: 79.321
Authors: Sean Wharton; Christiane L Haase; Elham Kamran; Aiden Liu; Johanna Mancini; Drew Neish; Arash Pakseresht; G Sarah Power; Rebecca A G Christensen Journal: Obes Sci Pract Date: 2020-05-09
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245